Organization | Varian Medical Systems

Varian Medical Systems Report issue

For profit Phase 1 Phase 2 Phase 3

Founded: Palo Alto CA United States (1948)

Status: Acquired by Agilent Technologies, Inc. (2009)

Organization Overview

First Clinical Trial

2012

NCT01752257

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2024

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Varian Medical | Varian Medical Systems | Varian Medical Systems, Inc.

Active Ingredients

Drugs in Phase 3 Trials (2)

doxorubicin (Doxil) (2 trials)

memantine (namenda) (1 trial)

Drugs in Phase 2 Trials (11)

carboplatin (paraplatin) (1 trial)

cisplatin (platinol) (1 trial)

fludeoxyglucose f-18 (1 trial)

gemcitabine (gemzar) (1 trial)

lutetium (177Lu) vipivotide tetraxetan (Pluvicto) (1 trial)

nivolumab (opdivo) (1 trial)

paclitaxel (taxol) (1 trial)

pembrolizumab (keytruda) (1 trial)

pemetrexed (alimta) (1 trial)

relugolix (ORGOVYX) (1 trial)

(s)-4-(3-fluoropropyl)-l-glutamic acid (1 trial)

Drugs in Phase 1 Trials (2)

pimonidazole (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Brain Neoplasms (Phase 3)

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Melanoma (Phase 1)

Neoplasm Metastasis (Phase 3)

Pancreatic Neoplasms (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 9
# of Trial APIs: 15